Allergic diseases are widespread and their incidence is on the increase. Mucosal immunoglobulin A (IgA) may prevent the entrance of allergens so that it may be important in the mediation of allergic diseases. Creative Biolabs has extensive experience to offer non-IgG therapeutic antibodies services for allergic diseases therapy. We also offer an extensive range of therapeutic antibodies specifically targeting a wide variety of diseases, especially tumors.
Introduction of Allergic Diseases
Allergic diseases, including allergic asthma, rhinitis and conjunctivitis, atopic dermatitis (AD), food and drug allergies, are common diseases affecting approximately 15% of the global population worldwide with an increasing incidence. Allergy has a negative impact on the quality of life since it probably leads to life-threatening diseases such as fatal asthma, swelling, low blood pressure, and other allergic reactions. It is becoming increasingly clear that allergies are systemic immune diseases caused by an inappropriate adaptive immune response to common allergens. The allergic reaction is biphasic, reacts immediately within minutes of exposure to the allergen, and a late response occurs several hours later. The immediate response is due to the release of pre-formed mediators from basophils and mast cells following cross-linking of IgE bound to high-affinity receptors on the cell surface. Among these processes, the IgE antibody plays a crucial role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making it particularly important in the treatment of IgE-mediated allergic diseases.
Fig.1 Abstract of allergy diseases. (Larsen, 2016)
IgA for Allergic Diseases
IgA normally neutralizes toxins and bacteria (viruses) on mucosal surfaces by mechanisms of interfering with its motility, competing for epithelial adhesion sites, and improving the viscoelasticity of airway secretions. In healthy individuals, allergen-specific IgA molecules not IgE are found, and their T cells are unable to proliferate in response to allergens, which probably results from the development of the regulatory process actively inhibits the response to allergens. It has been shown that allergen-specific monoclonal IgA alleviated allergic symptoms by recognizing the same allergen and reducing the immune response when previously IgE-sensitized mice exposed to allergens. Moreover, immunosuppression by IgA injection occurs even after allergen challenge in mice in a mouse epitope-dependent manner. Injection of monoclonal IgA antibody in patients with allergic symptoms, especially those who have already exposed to the allergen in the presence of IgE, could effectively alleviate allergic disease through its immunosuppressive effects. IgA has a protective effect on allergic diseases such as asthma due to the inverse relationship between it and allergic development. Therefore, the development of new therapies for allergic diseases based on or complementing the IgA strengthening strategy is promising.
Creative Biolabs develops and commercializes a full range of non-IgG therapeutic antibodies specifically targeting a wide variety of diseases based on our antibody engineering technology, phage display technology, and therapeutic antibody discovery platform. In addition to various antibodies products, we also provide a series of non-IgG antibodies development and engineering services for various applications according to customers’ demands. For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
- Larsen, J. N.; et al. Allergy immunotherapy: the future of allergy treatment. Drug discovery today. 2016, 21(1): 26-37.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
